DK0457250T3 - Bifunktionelle koblingsforbindelser, konjugater og fremgangsmåder til fremstilling deraf - Google Patents
Bifunktionelle koblingsforbindelser, konjugater og fremgangsmåder til fremstilling derafInfo
- Publication number
- DK0457250T3 DK0457250T3 DK91107737T DK91107737T DK0457250T3 DK 0457250 T3 DK0457250 T3 DK 0457250T3 DK 91107737 T DK91107737 T DK 91107737T DK 91107737 T DK91107737 T DK 91107737T DK 0457250 T3 DK0457250 T3 DK 0457250T3
- Authority
- DK
- Denmark
- Prior art keywords
- conjugates
- methods
- novel
- bifunctional compounds
- target
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/43—Y being a hetero atom
- C07C323/44—X or Y being nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cephalosporin Compounds (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Static Random-Access Memory (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Measurement Of Radiation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07522996 US5137877B1 (en) | 1990-05-14 | 1990-05-14 | Bifunctional linking compounds conjugates and methods for their production |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0457250T3 true DK0457250T3 (da) | 1999-11-29 |
Family
ID=24083237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK91107737T DK0457250T3 (da) | 1990-05-14 | 1991-05-13 | Bifunktionelle koblingsforbindelser, konjugater og fremgangsmåder til fremstilling deraf |
Country Status (14)
Country | Link |
---|---|
US (2) | US5137877B1 (fr) |
EP (1) | EP0457250B1 (fr) |
JP (2) | JP3010319B2 (fr) |
AT (1) | ATE182141T1 (fr) |
AU (1) | AU646850B2 (fr) |
CA (1) | CA2042503C (fr) |
DE (1) | DE69131435T2 (fr) |
DK (1) | DK0457250T3 (fr) |
ES (1) | ES2134761T3 (fr) |
FI (1) | FI100718B (fr) |
GR (1) | GR3031402T3 (fr) |
IE (1) | IE911635A1 (fr) |
PT (1) | PT97639B (fr) |
ZA (1) | ZA913591B (fr) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5622929A (en) * | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
US5474765A (en) * | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
AU3937693A (en) * | 1992-04-10 | 1993-11-18 | Brigham And Women's Hospital | Methods and compositions for oral delivery of therapeutic agents |
DE4236237A1 (de) * | 1992-10-27 | 1994-04-28 | Behringwerke Ag | Prodrugs, ihre Herstellung und Verwendung als Arzneimittel |
US5750088A (en) * | 1993-03-30 | 1998-05-12 | The Dupont Merck Pharmaceutical Company | Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals |
JPH09502263A (ja) * | 1993-08-27 | 1997-03-04 | アボツト・ラボラトリーズ | ヒドラジン誘導体化細胞 |
US5858327A (en) * | 1993-09-03 | 1999-01-12 | Resolutions Pharmaceuticals, Inc. | Hydrazino-type N2 S2 radionuclide chelating compounds |
US5502246A (en) * | 1994-03-22 | 1996-03-26 | Eli Lilly And Company | Solid-phase synthesis utilizing photochemical carbon-sulfur bond cleavage of thioethers |
US5599686A (en) * | 1994-06-28 | 1997-02-04 | Merck & Co., Inc. | Peptides |
US6143864A (en) * | 1994-06-28 | 2000-11-07 | Merck & Co., Inc. | Peptides |
US5866679A (en) * | 1994-06-28 | 1999-02-02 | Merck & Co., Inc. | Peptides |
US5856571A (en) * | 1995-06-07 | 1999-01-05 | Cellpro, Incorporated | Semicarbazide-containing linker compounds for formation of stably-linked conjugates and methods related thereto |
WO1997014416A1 (fr) * | 1995-10-18 | 1997-04-24 | Merck & Co., Inc. | Conjugues utiles pour traiter l'adenome prostatique benin |
ES2195036T3 (es) * | 1995-12-22 | 2003-12-01 | Bristol Myers Squibb Co | Conectores de hidrazona ramificados. |
US6177404B1 (en) | 1996-10-15 | 2001-01-23 | Merck & Co., Inc. | Conjugates useful in the treatment of benign prostatic hyperplasia |
US5948750A (en) * | 1996-10-30 | 1999-09-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
EP0941120A4 (fr) * | 1996-11-05 | 2004-08-18 | Bristol Myers Squibb Co | Sequences de liaison peptidiques ramifiees |
US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
US6127333A (en) * | 1997-07-10 | 2000-10-03 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US20030215421A1 (en) * | 1999-07-21 | 2003-11-20 | Mcdonald John R. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
US7157418B1 (en) | 1998-07-22 | 2007-01-02 | Osprey Pharmaceuticals, Ltd. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
US6299860B1 (en) * | 1998-10-15 | 2001-10-09 | Fluoro Probe, Inc. | Method for viewing diseased tissue located within a body cavity |
US6652836B2 (en) | 1998-10-15 | 2003-11-25 | Fluoroprobe, Inc. | Method for viewing tumor tissue located within a body cavity |
US6222093B1 (en) * | 1998-12-28 | 2001-04-24 | Rosetta Inpharmatics, Inc. | Methods for determining therapeutic index from gene expression profiles |
US6444657B1 (en) | 1998-12-31 | 2002-09-03 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
US7192729B2 (en) | 1999-07-06 | 2007-03-20 | General Atomics | Methods for assaying homocysteine |
WO2001062968A2 (fr) * | 2000-02-25 | 2001-08-30 | General Atomics | Enzymes de liaison nucleique mutantes et leur application dans le diagnostic, la detection et la purification |
WO2001071352A2 (fr) * | 2000-03-17 | 2001-09-27 | The Salk Institute For Biological Studies | Compositions associees a la formation de complexes et leurs procedes d'utilisation |
US6610504B1 (en) | 2000-04-10 | 2003-08-26 | General Atomics | Methods of determining SAM-dependent methyltransferase activity using a mutant SAH hydrolase |
GB0012718D0 (en) * | 2000-05-24 | 2000-07-19 | Angeletti P Ist Richerche Bio | Conjugates of aminodrugs |
WO2002013873A2 (fr) * | 2000-08-17 | 2002-02-21 | Synapse Technologies, Inc. | Compositions de composes conjugues a p97 et leurs methodes d'utilisation |
WO2002013843A2 (fr) * | 2000-08-17 | 2002-02-21 | University Of British Columbia | Agents chimiotherapeutiques conjugues avec p97, et leurs utilisations pour le traitement des tumeurs neurologiques |
US7445802B2 (en) * | 2000-12-26 | 2008-11-04 | Yeda Research And Development Co. Ltd | Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases |
IL154183A0 (en) | 2001-05-31 | 2003-07-31 | Medarex Inc | Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
US20030232760A1 (en) * | 2001-09-21 | 2003-12-18 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
RU2196604C1 (ru) * | 2001-12-21 | 2003-01-20 | Северин Евгений Сергеевич | Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе |
US7282590B2 (en) * | 2004-02-12 | 2007-10-16 | The Research Foundation Of State University Of New York | Drug conjugates |
US7384760B2 (en) * | 2004-04-30 | 2008-06-10 | General Atomics | Methods for assaying inhibitors of S-adenosylhomocysteine (SAH) hydrolase and S-adenosylmethionine (SAM)-dependent methyltransferase |
JP4806680B2 (ja) * | 2004-05-19 | 2011-11-02 | メダレックス インコーポレイテッド | 自己犠牲リンカー及び薬剤複合体 |
US7691962B2 (en) * | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
US7541330B2 (en) * | 2004-06-15 | 2009-06-02 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
WO2006012527A1 (fr) * | 2004-07-23 | 2006-02-02 | Endocyte, Inc. | Groupes de liaison bivalents et conjugués de ceux-ci |
AU2006214031A1 (en) * | 2005-02-18 | 2006-08-24 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen (PSMA) |
US7714016B2 (en) * | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
NZ565964A (en) * | 2005-08-24 | 2011-11-25 | Immunogen Inc | Process for preparing maytansinoid antibody conjugates by purifying with tangential flow filtration |
AU2006294554B2 (en) * | 2005-09-26 | 2013-03-21 | E. R. Squibb & Sons, L.L.C. | Antibody-drug conjugates and methods of use |
PL1940789T3 (pl) | 2005-10-26 | 2012-04-30 | Squibb & Sons Llc | Metody i związki do otrzymywania analogów cc-1065 |
WO2007059404A2 (fr) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Composes et conjugues cytotoxiques |
TWI412367B (zh) | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
CA2678514A1 (fr) * | 2007-02-21 | 2008-08-28 | Medarex, Inc. | Liants chimiques avec acides amines uniques et conjugues de ceux-ci |
CA2688240A1 (fr) | 2007-05-24 | 2008-12-04 | The United States Government As Represented By The Department Of Veterans Affairs | Transduction de proteines intranucleaires par voie de recuperation des nucleosides |
WO2009039207A1 (fr) * | 2007-09-19 | 2009-03-26 | Oncofluor, Inc. | Procédé d'imagerie et de traitement d'organes et de tissus |
AU2015202204A1 (en) * | 2008-04-30 | 2015-05-14 | Immunogen, Inc. | Cross-linkers and their uses |
PL2281006T3 (pl) | 2008-04-30 | 2018-01-31 | Immunogen Inc | Środki łączące i ich zastosowania |
EP2297178B1 (fr) * | 2008-05-27 | 2014-07-30 | Genzyme Corporation | Analogues peptidiques de l'hormone de stimulation d'alpha-melanocytes |
KR101413480B1 (ko) | 2008-12-05 | 2014-07-10 | 아브락시스 바이오사이언스, 엘엘씨 | Sparc 결합 펩티드와 이들의 용도 |
US9155801B2 (en) | 2009-05-28 | 2015-10-13 | The United States Government As Represented By The Department Of Veterans Affairs | Amino acid sequences which enhance peptide conjugate solubility |
SG176068A1 (en) | 2009-06-03 | 2011-12-29 | Immunogen Inc | Conjugation methods |
GB201012410D0 (en) | 2010-07-23 | 2010-09-08 | Medical Res Council | Intracellular immunity |
SI2691155T1 (sl) | 2011-03-29 | 2019-03-29 | Immunogen, Inc. | Priprava majtanzinoidnih konjugatov protiteles v postopku z enim korakom |
EP2592103A1 (fr) | 2011-11-08 | 2013-05-15 | Adriacell S.p.A. | Dérivés d'aldéhyde de polymère |
GB201202268D0 (en) | 2012-02-09 | 2012-03-28 | Medical Res Council | Intracellular immunity |
JP6345181B2 (ja) | 2012-10-04 | 2018-06-20 | イムノゲン インコーポレーティッド | 細胞結合剤細胞毒性剤コンジュゲートを精製するためのpvdf膜の使用 |
ES2701076T3 (es) | 2012-11-24 | 2019-02-20 | Hangzhou Dac Biotech Co Ltd | Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células |
CA2906784C (fr) | 2013-03-15 | 2023-02-28 | The Centre For Drug Research And Development | Composes cytotoxiques et antimitotiques et leurs procedes d'utilisation |
WO2015095953A1 (fr) | 2013-12-27 | 2015-07-02 | The Centre For Drug Research And Development | Systèmes de liaison contenant un sulfonamide pour conjugués de médicaments |
MX2016008448A (es) | 2013-12-27 | 2017-01-09 | Zymeworks Inc | Conjugados de var2csa-farmaco. |
WO2015127685A1 (fr) | 2014-02-28 | 2015-09-03 | Hangzhou Dac Biotech Co., Ltd | Lieurs chargés et leurs utilisations pour la conjugaison |
KR102494557B1 (ko) | 2014-09-17 | 2023-02-02 | 자임워크스 비씨 인코포레이티드 | 세포독성 및 항유사분열성 화합물, 그리고 이를 이용하는 방법 |
EP3215537B1 (fr) | 2014-11-05 | 2022-01-05 | Nanyang Technological University | Domaine vh stabilisé et autonome d'un anticorps |
CN113350518A (zh) | 2015-07-12 | 2021-09-07 | 杭州多禧生物科技有限公司 | 与细胞结合分子的共轭偶联的桥连接体 |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
US9989535B2 (en) * | 2015-10-01 | 2018-06-05 | Warp Drive Bio, Inc. | Methods and reagents for analyzing protein-protein interfaces |
US20190330317A1 (en) | 2016-06-15 | 2019-10-31 | Yale University | Anti-guanosine antibody as a molecular delivery vehicle |
US10517958B2 (en) | 2016-10-04 | 2019-12-31 | Zymeworks Inc. | Compositions and methods for the treatment of platinum-drug resistant cancer |
CN116143678A (zh) | 2016-11-14 | 2023-05-23 | 杭州多禧生物科技有限公司 | 偶联连接体,含有此连接体的细胞结合分子-药物偶联物及其制备和应用 |
US20210054102A1 (en) | 2018-02-01 | 2021-02-25 | Yale University | Compositions and methods for enhancing nuclear translocation |
WO2022013613A2 (fr) | 2020-07-17 | 2022-01-20 | Onena Medicines S.L. | Anticorps dirigés contre des protéines lefty |
CN113262311B (zh) * | 2021-04-29 | 2022-08-05 | 武汉纳乐吉生命科技有限公司 | 肿瘤特异性刺激响应的羟烷基淀粉-阿霉素偶联物、其制备和应用 |
WO2023010060A2 (fr) | 2021-07-27 | 2023-02-02 | Novab, Inc. | Anticorps anti-vlrb génétiquement modifiés présentant des fonctions effectrices immunitaires |
WO2023056450A1 (fr) | 2021-09-30 | 2023-04-06 | Yale University | Compositions et méthodes pour le traitement de la polykystose rénale autosomique dominante et d'autres maladies ayant une activité de mtor régulée à la hausse |
WO2024050524A1 (fr) | 2022-09-01 | 2024-03-07 | University Of Georgia Research Foundation, Inc. | Compositions et procédés de direction de l'apolipoprotéine l1 en vue d'induire la mort de cellules de mammifère |
WO2024064752A2 (fr) | 2022-09-20 | 2024-03-28 | Yale University | Compositions d'adhésifs humides dérivés d'adhésines de biofilm vibrio cholerae et procédés associés |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1470054A1 (de) * | 1963-11-09 | 1969-05-29 | Merck Ag E | Schwefelhaltige Pyridin-Derivate und Verfahren zu deren Herstellung |
US4130562A (en) * | 1975-01-10 | 1978-12-19 | Givaudan Corporation | Odorant or flavoring thiazolyl disulphides |
SE430062B (sv) * | 1977-03-04 | 1983-10-17 | Pharmacia Fine Chemicals Ab | Kopplings- eller tioleringsreagens |
US4112217A (en) * | 1977-09-02 | 1978-09-05 | Sri International | Bis-hydrazones of daunomycin and adriamycin |
US4250303A (en) * | 1977-10-17 | 1981-02-10 | Sri International | N-Benzyl anthracyclines |
US4258193A (en) * | 1978-07-13 | 1981-03-24 | Toyo Jozo Kabushiki Kaisha | Disulfide derivatives having S--S exchange reactivity |
US4303785A (en) * | 1978-08-05 | 1981-12-01 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Antitumor anthracycline antibiotics |
US4202967A (en) * | 1978-10-02 | 1980-05-13 | Sri International | N,N-pentamethylene derivatives of daunomycin and adriamycin |
US4282031A (en) * | 1979-01-03 | 1981-08-04 | Gulf Oil Corporation | Substituted thiosemicarbazides, their manufacture and use as plant growth regulants |
US4252962A (en) * | 1980-03-24 | 1981-02-24 | Olin Corporation | Process for producing 2-amino or selected 2-(substituted)amino-5-mercapto-1,3,4-thiadiazole compounds |
US4301277A (en) * | 1980-10-20 | 1981-11-17 | Sri International | 3-Deamino-3-(4-morpholinyl) derivatives of daunorubicin and doxorubicin |
US4314054A (en) * | 1981-03-23 | 1982-02-02 | Sri International | 3'-Deamino-3'-(4-methoxy-1-piperidinyl) derivatives of daunorubicin and doxorubicin |
SE8102193L (sv) * | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och dess anvendning |
GB2116979B (en) * | 1982-02-25 | 1985-05-15 | Ward Page Faulk | Conjugates of proteins with anti-tumour agents |
US5162512A (en) * | 1982-03-09 | 1992-11-10 | Cytogen Corporation | Amine derivatives of anthracycline antibodies |
ATE25197T1 (de) * | 1982-05-12 | 1987-02-15 | Harvard College | Hybridproteinekodierende fusionierte gene, sie enthaltende klonierungsvektoren und deren verwendung. |
GB2122612B (en) * | 1982-06-16 | 1985-09-25 | May & Baker Ltd | Cystamine derivatives |
US4464529A (en) * | 1982-07-20 | 1984-08-07 | Sri International | Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin |
US4590001A (en) * | 1983-03-28 | 1986-05-20 | Stjernholm Rune L | Platinum bound to transferrin for use in the treatment of breast tumors |
SE8302758L (sv) * | 1983-05-17 | 1984-11-18 | Pharmacia Ab | Sett for uppspjelkning av disulfidbindningar och derigenom erhallen forening |
US4545985A (en) * | 1984-01-26 | 1985-10-08 | The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services | Pseudomonas exotoxin conjugate immunotoxins |
US4522750A (en) * | 1984-02-21 | 1985-06-11 | Eli Lilly And Company | Cytotoxic compositions of transferrin coupled to vinca alkaloids |
JPS6157579A (ja) * | 1984-08-29 | 1986-03-24 | Toyama Chem Co Ltd | 3−アミノピロリジンまたはその塩の製造法 |
US4591637A (en) * | 1985-01-17 | 1986-05-27 | Sri International | Open chain-morpholino adriamycins |
JPS61274658A (ja) * | 1985-05-29 | 1986-12-04 | Morii Shokuhin Kk | 半生状はるさめの製造方法 |
US4797491A (en) * | 1986-03-17 | 1989-01-10 | Cetus Corporation | Compound 1-(3-(2-pyridyldithio)propionamido)-12-(5-hydrazidoglutaramido)-4,9-dioxadodecane |
IN165717B (fr) * | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
US4970303A (en) * | 1988-02-03 | 1990-11-13 | Xoma Corporation | Linking agents and methods |
IL89220A (en) * | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Immunoconjugates of anthracycline, their production and pharmaceutical preparations containing them |
US5157123A (en) * | 1989-03-13 | 1992-10-20 | Georgetown University | S-(2-thiopyridyl)-l-cysteine, a heterobifunctional crosslinking reagent |
-
1990
- 1990-05-14 US US07522996 patent/US5137877B1/en not_active Expired - Lifetime
-
1991
- 1991-04-03 AU AU74038/91A patent/AU646850B2/en not_active Ceased
- 1991-05-10 JP JP3199757A patent/JP3010319B2/ja not_active Expired - Fee Related
- 1991-05-10 FI FI912285A patent/FI100718B/fi not_active IP Right Cessation
- 1991-05-10 PT PT97639A patent/PT97639B/pt active IP Right Grant
- 1991-05-13 ZA ZA913591A patent/ZA913591B/xx unknown
- 1991-05-13 DK DK91107737T patent/DK0457250T3/da active
- 1991-05-13 DE DE69131435T patent/DE69131435T2/de not_active Expired - Fee Related
- 1991-05-13 AT AT91107737T patent/ATE182141T1/de not_active IP Right Cessation
- 1991-05-13 ES ES91107737T patent/ES2134761T3/es not_active Expired - Lifetime
- 1991-05-13 IE IE163591A patent/IE911635A1/en not_active IP Right Cessation
- 1991-05-13 EP EP91107737A patent/EP0457250B1/fr not_active Expired - Lifetime
- 1991-05-14 CA CA002042503A patent/CA2042503C/fr not_active Expired - Fee Related
-
1992
- 1992-04-08 US US07/865,062 patent/US5349066A/en not_active Expired - Fee Related
-
1999
- 1999-05-12 JP JP13158399A patent/JP3234980B2/ja not_active Expired - Fee Related
- 1999-09-30 GR GR990402493T patent/GR3031402T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP0457250A3 (en) | 1992-07-01 |
US5137877A (en) | 1992-08-11 |
IE911635A1 (en) | 1991-11-20 |
CA2042503C (fr) | 2002-07-23 |
CA2042503A1 (fr) | 1991-11-15 |
PT97639A (pt) | 1992-02-28 |
ES2134761T3 (es) | 1999-10-16 |
EP0457250B1 (fr) | 1999-07-14 |
FI912285A0 (fi) | 1991-05-10 |
FI912285A (fi) | 1991-11-15 |
DE69131435T2 (de) | 2000-03-23 |
PT97639B (pt) | 1998-08-31 |
DE69131435D1 (de) | 1999-08-19 |
JP3010319B2 (ja) | 2000-02-21 |
FI100718B (fi) | 1998-02-13 |
JP3234980B2 (ja) | 2001-12-04 |
EP0457250A2 (fr) | 1991-11-21 |
AU646850B2 (en) | 1994-03-10 |
US5137877B1 (en) | 1996-01-30 |
GR3031402T3 (en) | 2000-01-31 |
ZA913591B (en) | 1992-02-26 |
JP2000026404A (ja) | 2000-01-25 |
ATE182141T1 (de) | 1999-07-15 |
AU7403891A (en) | 1991-11-14 |
US5349066A (en) | 1994-09-20 |
JPH04352765A (ja) | 1992-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5137877B1 (en) | Bifunctional linking compounds conjugates and methods for their production | |
US6083926A (en) | Water soluble vitamin B12 receptor modulating agents and methods related thereto | |
US4263279A (en) | Pharmaceutically active compositions containing adriamycin and daunomycin | |
JPH02152993A (ja) | アンチマーおよびアンチマー複合体 | |
JPH03502098A (ja) | 酸性化された細胞内小胞内で開裂可能な蛋白質架橋試薬 | |
JPS6112630A (ja) | 免疫毒素およびその製造法 | |
EP0368668B1 (fr) | Conjugués anticorps-médicament | |
IL94379A0 (en) | Anthracycline conjugates having a novel linker,their production and pharmaceutical compositions containing them | |
IL64722A (en) | Immunoglobulin conjugates,their preparation and pharmaceutical compositions containing them | |
CA1224718A (fr) | Agents antitumoraux contenant des complexes du platine | |
EP1015475A1 (fr) | Agents de modulation des recepteurs de la vitamine b 12? | |
CA1252719A (fr) | PREPARATION DE PRODUITS CONJUGUES D'ADENINE-9-.beta.- ARABINOFURANOSIDE-5-MONOPHOSPHATE AVEC DE L'ALBUMINE HUMAINE LACTOSAMINEE, PRODUITS CONJUGUES OBTENUS ET COMPOSITION THERAPEUTIQUE QUI EN RENFERME | |
US20230330245A1 (en) | Antibody-exatecan conjugates | |
JPS62116522A (ja) | 抗腫瘍剤 | |
JPS6284027A (ja) | 抗腫瘍剤 | |
AU7164700A (en) | Vitamin B12 receptor modulating agents and methods related thereto | |
CA2010164A1 (fr) | Immunoconjugats d'anthracycline et methode de production |